Back to Search Start Over

Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma

Authors :
Pasvolsky, Oren
Milton, Denái R.
Rauf, Mikael
Tanner, Mark R.
Bashir, Qaiser
Srour, Samer
Tang, Guilin
Saini, Neeraj
Ramdial, Jeremy
Masood, Adeel
Nieto, Yago
Lee, Hans C.
Patel, Krina K.
Kebriaei, Partow
Thomas, Sheeba K.
Weber, Donna M.
Orlowski, Robert Z.
Shpall, Elizabeth J.
Champlin, Richard E.
Qazilbash, Muzaffar H.
Source :
Transplantation and Cellular Therapy; November 2022, Vol. 28 Issue: 11 p752.e1-752.e6, 6p
Publication Year :
2022

Abstract

•This was a retrospective analysis of 231 patients with a high-risk chromosomal abnormality (HRMM) receiving lenalidomide (Len)-based post-transplantation maintenance.•Maintenance with Len-based combinations did not improve outcomes in the entire cohort.•In patients with HRMM other than 1q+, there was a trend toward improved PFS with Len-based combinations for maintenance.

Details

Language :
English
ISSN :
26666375 and 26666367
Volume :
28
Issue :
11
Database :
Supplemental Index
Journal :
Transplantation and Cellular Therapy
Publication Type :
Periodical
Accession number :
ejs61353626
Full Text :
https://doi.org/10.1016/j.jtct.2022.07.028